实体器官移植术后巨细胞病毒肺炎的防治策略——ATS巨细胞病毒肺炎的诊治指南解读

巨春蓉; 韦兵; 练巧燕; 陈奥; 徐鑫; 黄丹霞; 陈荣昌

doi:10.3969/j.issn.1674-7445.2019.01.014

实体器官移植术后巨细胞病毒肺炎的防治策略——ATS巨细胞病毒肺炎的诊治指南解读

doi: 10.3969/j.issn.1674-7445.2019.01.014

510012 广州医科大学附属第一医院广州呼吸健康研究院

基金项目:

广东省自然科学基金 2018A030313107

广州呼吸健康研究院青年基金项目 20181001

详细信息

作者简介:
巨春蓉，女，1977年生，博士，主任医师，研究方向为实体器官移植术后肺部并发症，Email：juchunrongju@126.com

通讯作者:
陈荣昌，男，1959年生，博士，主任医师，博士研究生导师，研究方向为感染性肺疾病，Email：chenrc_1234@163.com

中图分类号: R617, R619+.3
计量
- 文章访问数: 228
- HTML全文浏览量: 116
- PDF下载量: 36
- 被引次数: 0
出版历程
- 收稿日期: 2018-10-18
- 网络出版日期: 2021-01-19
- 刊出日期: 2019-01-15

Prevention and treatment strategy of cytomegalovirus pneumonia after solid organ transplantation: interpretation of the diagnosis and treatment of ATS cytomegalovirus pneumonia

摘要

摘要: 巨细胞病毒（CMV）肺炎是实体器官移植（SOT）受体最常见的感染性并发症之一，其中肺移植受体术后CMV肺炎的发生率明显高于其他SOT受体。CMV肺炎一旦发生，病情进展迅速、病死率高。针对CMV的预防性用药可以显著降低感染发生率及其相关病死率。本文根据2013年美国胸科学会（ATS）国际指南对CMV肺炎的高危因素、诊断标准及防治策略进行解读并综述。
- 巨细胞病毒 /
- 器官移植 /
- 术后感染 /
- 肺炎 /
- 实体器官移植 /
- 更昔洛韦 /
- 缬更昔洛韦

HTML全文

参考文献(18)

[1]	BEAM E, RAZONABLE RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment[J]. Curr Infect Dis Rep, 2012, 14(6):633-641. DOI: 10.1007/s11908-012-0292-2.
[2]	白纪民, 李浩, 张晓明, 等.肾移植术后巨细胞病毒感染的危险因素分析和血清甘露聚糖结合凝集素的预测价值[J].器官移植, 2013, 4(2):79-83. DOI: 10.3969/j.issn.1674-7445.2013.02.004. BAI JM, LI H, ZHANG XM, et al. Risk factors of cytomegalovirus infection and the predictive value of mannose-binding lectin after renal transplantation[J]. Organ Transplant, 2013, 4(2):79-83. DOI: 10.3969/j.issn.1674-7445.2013.02.004.
[3]	HALLECK F, KHADZHYNOV D, SCHREZENMEIER E, et al. Prolonged low-dose prophylaxis with valganciclovir in cytomegalovirus-negative recipients of kidney transplants from cytomegalovirus-positive donors allows seroconversion and prevents cytomegalovirus disease[J]. Transplant Proc, 2017, 49(10):2280-2284. DOI: 10.1016/j.transproceed.2017.10.0 04.
[4]	MEESING A, RAZONABLE RR. Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation[J]. Expert Rev Clin Pharmacol, 2018, 11(8):773-788. DOI: 10.1080/17512433.2018.1501557.
[5]	STRUEBER M, WARNECKE G, FUGE J, et al. Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial[J]. Am J Transplant, 2016, 16(11):3171-3180. DOI: 10.1111/ajt.13835.
[6]	KOTTON CN, KUMAR D, CALIENDO AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation[J]. Transplantation, 2013, 96(4):333-360. DOI: 10.1097/TP.0b013e31829df29d.
[7]	BEAM E, GERMER JJ, LAHR B, et al. Cytomegalovirus (CMV) DNA quantification in bronchoalveolar lavage fluid of immunocompromised patients with CMV pneumonia[J]. Clin Transplant, 2018, 32(1). DOI: 10.1111/ctr.13149.
[8]	KOTTON CN, KUMAR D, CALIENDO AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation[J]. Transplantation, 2018, 102(6):900-931. DOI: 10.1097/TP.0000000000002191.
[9]	HUMAR A, LIMAYE AP, BLUMBERG EA, et al. Extended valganciclovir prophylaxis in D⁺/R^- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study[J]. Transplantation, 2010, 90(12):1427-1431. doi: 10.1097/TP.0b013e3181ff1493
[10]	WⅡTA AP, ROUBINIAN N, KHAN Y, et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis[J]. Transpl Infect Dis, 2012, 14(3):248-258. DOI: 10.1111/j.1399-3062.2012.00723.x.
[11]	AVERY RK, ARAV-BOGER R, MARR KA, et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection[J]. Transplantation, 2016, 100(10):e74-e80. DOI: 10.1097/TP.0000000000001418.
[12]	LITJENS NHR, VAN DER WAGEN L, KUBALL J, et al. Potential beneficial effects of cytomegalovirus infection after transplantation[J]. Front Immunol, 2018, 9:389. DOI: 10.3389/fimmu.2018.00389.
[13]	LISBOA LF, PREIKSAITIS JK, HUMAR A, et al. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients[J]. Transplantation, 2011, 92(9):1063-1068. DOI: 10.1097/TP.0b013e31822fa4b7.
[14]	BRUMINHENT J, ROTJANAPAN P, WATCHARANANAN SP. Epidemiologyand outcome of ganciclovir-resistant cytomegalovirus infection after solid organ transplantation: a single transplant center experience in Thailand[J]. Transplant Proc, 2017, 49(5):1048-1052. DOI: 10.1016/j.transproceed.2017.03.053.
[15]	KOVAL CE. Prevention and treatment of cytomegalovirus infections in solid organ transplant recipients[J]. Infect Dis Clin North Am, 2018, 32(3):581-597. DOI: 10.1016/j.idc.2018.04.008.
[16]	ROLLING KE, JORGENSON MR, DESCOUROUEZ JL, et al. Ganciclovir-resistant cytomegalovirus infection in abdominal solid organ transplant recipients: case series and review of the literature[J]. Pharmacotherapy, 2017, 37(10):1258-1271. DOI: 10.1002/phar.1987.
[17]	KAUL DR, STOELBEN S, COBER E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246[J]. Am J Transplant, 2011, 11(5):1079-1084. DOI: 10.1111/j.1600-6143.2011.03530.x.
[18]	GRIFFITHS PD, STANTON A, MCCARRELL E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial[J]. Lancet, 2011, 377(9773):1256-1263. DOI: 10.1016/S0140-6736(11)60136-0.